GRTX · As filed with the SEC
Galera Therapeutics balance sheet, by fiscal year
The statement as Galera Therapeutics presents it in its 10-Q and 10-K: its own lines, labels and order. Tables over time lines up standardized figures across every filing.
CONSOLIDATED BALANCE SHEETS · USD
| USD | FY2025 Dec 31, 2025 | FY2024 Dec 31, 2024 | FY2023 Dec 31, 2023 | FY2022 Dec 31, 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| Current assets: | ||||
| Cash and cash equivalents | 6,375,000 | 8,289,000 | 18,257,000 | 4,266,000 |
| Short-Term Investments | — | — | 0 | 27,331,000 |
| Restricted cash | — | — | 0 | 50,000 |
| Refundable PDUFA fee | — | — | 0 | 3,242,000 |
| Subscription receivable | 0 | 635,000 | — | — |
| Prepaid expenses and other current assets | 720,000 | 1,077,000 | 3,372,000 | 3,646,000 |
| Total current assets | 7,095,000 | 10,001,000 | 21,629,000 | 38,535,000 |
| Property and equipment, net | — | 0 | 71,000 | 438,000 |
| Acquired intangible asset | — | 0 | 2,258,000 | 2,258,000 |
| Goodwill | — | 0 | 881,000 | 881,000 |
| Right-of-use lease assets | — | 0 | 1,212,000 | 43,000 |
| Other assets | 101,000 | 100,000 | 90,000 | 1,881,000 |
| Total assets | 7,196,000 | 10,101,000 | 26,141,000 | 44,036,000 |
| LIABILITIES AND STOCKHOLDERS’ EQUITY | ||||
| Current Liabilities: | ||||
| Accounts payable | 265,000 | 1,275,000 | 1,375,000 | 3,581,000 |
| Accrued expenses | 380,000 | 391,000 | 3,449,000 | 9,754,000 |
| Lease liabilities | — | 0 | 133,000 | 44,000 |
| Total current liabilities | 645,000 | 1,666,000 | 4,957,000 | 13,379,000 |
| Royalty purchase liability | 0 | 151,049,000 | 151,049,000 | 139,635,000 |
| Lease liabilities, net of current portion | — | 0 | 1,117,000 | 0 |
| Warrant liability | 0 | 1,055,000 | — | — |
| Deferred tax liability | — | 0 | 203,000 | 203,000 |
| Total liabilities | 645,000 | 153,770,000 | 157,326,000 | 153,217,000 |
| Stockholders’ Equity: | ||||
| Series B redeemable convertible preferred stock, $0.001 par value: 10,000,000 shares authorized; 119,318 shares issued and outstanding at December 31, 2025 and 2024 | — | — | 0 | 0 |
| Series B Redeemable Convertible Preferred Stock | 2,577,000 | 4,372,000 | — | — |
| Common stock, $0.001 par value: 200,000,000 shares authorized; 75,462,390 shares issued and outstanding at December 31, 2025 and 2024 | 75,000 | 75,000 | 54,000 | 28,000 |
| Additional paid-in capital | 311,213,000 | 308,247,000 | 306,167,000 | 269,137,000 |
| Accumulated other comprehensive loss | — | — | 0 | (22,000) |
| Accumulated deficit | (307,314,000) | (456,363,000) | (437,406,000) | (378,324,000) |
| Total stockholders' deficit | 3,974,000 | (148,041,000) | (131,185,000) | (109,181,000) |
| Total liabilities, redeemable convertible preferred stock and stockholders' deficit | 7,196,000 | 10,101,000 | 26,141,000 | 44,036,000 |
As filed on EDGAR · Not affiliated with the U.S. SEC · Not investment advice. Each column links to its filing.